SCHEMBL22025293

SCHEMBL22025293

CC(=O)Nc1ccc(C(=O)Nc2ccc(N)c(C)c2)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 11/20 0.64
CACNA1B Q00975 1/20 0.59
APBA1 Q02410 1/20 0.59
RAB9A P51151 4/20 0.57
NPC1 O15118 3/20 0.57
KMT2A Q03164 3/20 0.57
HDAC3 O15379 3/20 0.57
HDAC2 Q92769 3/20 0.57
NCOR2 Q9Y618 1/20 0.57
POLB P06746 2/20 0.55
ALDH1A1 P00352 1/20 0.55
HPGD P15428 1/20 0.55
MAPT P10636 1/20 0.55
MEN1 O00255 2/20 0.53
LMNA P02545 1/20 0.53
PKM P14618 1/20 0.53
APEX1 P27695 1/20 0.53
TDP1 Q9NUW8 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.51
HDAC4 P56524 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26416447 0.92 RAB9A (0.61) HDAC1RAB9ANPC1KMT2APOLB
SCHEMBL1832506 0.89 ALDH1A1 (0.57) HDAC1RAB9ANPC1KMT2AALDH1A1
SCHEMBL11493901 0.88 KMT2A (0.66) HDAC1RAB9ANPC1KMT2AHDAC3
SCHEMBL11594692 0.88 RAB9A (0.66) RAB9ANPC1KMT2APOLBALDH1A1
SCHEMBL4658995 0.87 RAB9A (0.55) HDAC1RAB9ANPC1KMT2APOLB
SCHEMBL22066391 0.87 RAB9A (0.56) CACNA1BAPBA1RAB9ANPC1KMT2A
SCHEMBL27888577 0.86 KMT2A (0.59) HDAC1RAB9ANPC1KMT2APOLB
SCHEMBL17744810 0.85 NPC1 (0.58) HDAC1RAB9ANPC1KMT2APOLB
SCHEMBL3530325 0.84 KMT2A (0.69) CACNA1BAPBA1RAB9ANPC1KMT2A
SCHEMBL27905354 0.84 HDAC1 (0.58) HDAC1CACNA1BAPBA1RAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11352354-B2 Substituted penta-fused hexa-heterocyclic compounds, preparation method therefor, drug combination and use thereof XIAMEN UNIVERSITY (CN) 2022-06-07 US disclosed
EP-3663293-A1 SUBSTITUTED PENTA- AND HEXA-HETEROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR, DRUG COMBINATION AND USE THEREOF Xiamen University (CN) 2020-06-10 EP disclosed
US-20200165246-A1 SUBSTITUTED PENTA-FUSED HEXA-HETEROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR, DRUG COMBINATION AND USE THEREOF XIAMEN UNIVERSITY (CN) 2020-05-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11352354-B2 Substituted penta-fused hexa-heterocyclic compounds, preparation method therefor, drug combination and use thereof PIKFYVE, PIK3CA, PIK3C2A HDAC1 856/4885CACNA1B 1814/4885APBA1 3441/4885
US-20200165246-A1 SUBSTITUTED PENTA-FUSED HEXA-HETEROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR, DRUG COMBINATION AND USE THEREOF PIKFYVE, PIK3CA, PIK3C2A HDAC1 856/4885CACNA1B 1814/4885APBA1 3441/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.